As of Nov 17
| 0.00 / 0.00%|
The 24 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 480.00, with a high estimate of 605.00 and a low estimate of 395.00. The median estimate represents a +22.58% increase from the last price of 391.59.
The current consensus among 28 polled investment analysts is to Hold stock in Regeneron Pharmaceuticals. This rating has held steady since November, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.